Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

It would behoove more Americans to learn how consistent seafood consumption has strong potential to ward off coronary disease ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Taylor Fritz blames opponent for Wimbledon curfew controversy after match suspended A trucker in his late 70s who can't ...

Now, Lilly has reinforced that finding with a strong of other measures, including that 32% of people taking Zepbound were able to lose a quarter of their body weight compared to 16% of the Wegovy ...

IQVIA figures on prescriptions for Zepbound and Wegovy, reported by Reuters, suggest that there were nearly 339,000 scrips for Lilly's product in the week ending 18th April, overtaking Novo ...